Drug Profile
Research programme: depressive disorder diagnostics and therapeutics - Toronto Innovation Acceleration Partners/Johnson & Johnson/CAMH
Latest Information Update: 07 Oct 2020
Price :
$50
*
At a glance
- Originator Centre for Addiction and Mental Health
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Major depressive disorder in Canada
- 28 Feb 2019 No recent reports of development identified for research development in Major depressive disorder(Diagnosis) in Canada
- 12 Jan 2015 Early research in Diagnostic tests in Canada (unspecified route)